Eli Lilly and Company India (Lilly) and Boehringer Ingelheim India,announce the launch of HumaPen Savvio, an innovative insulin delivery pen that meets the diabetics’ individual need. Engineered to resemble a small personal accessory rather than a medical device, this latest innovation was designed following feedback from people with diabetes who shared their aspiration to manage diabetes discreetly. HumaPen Savvio, an invention by Lilly, offers an extended shelf life of up to six years after first use.
HumaPen Savvio, an original research product of Lilly will be co-promoted by the Lilly-Boehringer Ingelheim alliance in India. It is short in size, lightweight, dependable, durable, easy to use insulin pen that will improve the everyday lives of people with diabetes. To boost the personal confidence of diabetics, the device is designed similar to a fashionable, compact pen with durable design and will be available in a range of colours – red, graphite, green and silver. HumaPen Savvio also makes dosing easy and insulin delivery discreet, which helps insulin users feel more at ease when using their medication.
Announcing the launch, Edgard Olaizola, Managing Director, Eli Lilly and Company India said “The launch of HumaPen Savvio marks an important milestone for Lilly, reflecting our ongoing commitment to develop ‘people-led’ innovative solutions for diabetes. At Lilly, we recognise that people are unique and that their insulin delivery devices should reflect their lifestyle and personality. That’s why we developed HumaPen Savvio to be lightweight, portable and available in a choice of colors. It will help to bring a greater sense of normalcy to using insulin. We will continue to introduce innovative products to address the unmet needs of patients amidst the growing Indian diabetes epidemic.”
Commenting on the launch, Sharad Tyagi, Managing Director, Boehringer Ingelheim India said, “After the successful launch of Trajenta by the Lilly-Boehringer Ingelheim Alliance, this is another revolutionary product for the huge diabetes market in India. HumaPen Savvio is in line with alliance’s ongoing commitment to provide innovative solutions for diabetes treatment. We are constantly working towards pioneering interventions by leveraging scientific know-how and commercial capabilities of both companies and expanding our product portfolio for diabetes in India.”
As per a patient perception study conducted in July 2013*, Lilly found that the most valued features of an insulin delivery device are ease of operation, convenience of use, accurate dosing, portability and easy dialing. The study group perceived HumaPen Savvio as better than other delivery devices available in market on most parameters including, ease of use, insufficient remaining dosage feature, stylish, sleek and discreet design being the differentiators.
HumaPen Savvio will be available in India across six metros; Delhi, Mumbai, Kolkata, Chennai, Hyderabad and Bangalore for use with 3 mL insulin cartridges Humalog, Humalog Mix25 and Humalog Mix50 on doctor’s prescription.
EP News Bureau– Mumbai
- Advertisement -
